{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T21:35:33Z","timestamp":1789076133962,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2023ZD0510400"],"award-info":[{"award-number":["2023ZD0510400"]}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"crossref","award":["Y-SYBLD2022RWR-0017"],"award-info":[{"award-number":["Y-SYBLD2022RWR-0017"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences","award":["2021-I2M-1-017"],"award-info":[{"award-number":["2021-I2M-1-017"]}]},{"name":"Tianjin Municipal Science and Technology Commission Grant","award":["21JCZDJC01170"],"award-info":[{"award-number":["21JCZDJC01170"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"DOI":"10.1186\/s12941-025-00801-y","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T13:59:27Z","timestamp":1748527167000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antibiotic stewardship in hematological patients with Escherichia coli and Klebsiella pneumoniae bloodstream infections: evaluating short-course and carbapenem-sparing strategies"],"prefix":"10.1186","volume":"24","author":[{"given":"Yuqing","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomeng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingsong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisi","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhou","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchang","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengkui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erlie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhe","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sizhou","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"issue":"5","key":"801_CR1","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1016\/S2666-5247(23)00119-2","volume":"4","author":"S Bagcchi","year":"2023","unstructured":"Bagcchi S. AMR in bacteria from humans, animals, and food in Europe. Lancet Microbe. 2023;4(5):e299.","journal-title":"Lancet Microbe"},{"key":"801_CR2","doi-asserted-by":"crossref","unstructured":"Cohn J, Mendelson M, Kanj SS et al. Accelerating antibiotic access and stewardship: a new model to safeguard public health. Lancet Infect Dis, 2024: S1473-3099(24)00070\u2013\u20097.","DOI":"10.1016\/S1473-3099(24)00070-7"},{"issue":"4","key":"801_CR3","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2011;52(4):e56\u201393.","journal-title":"Clin Infect Diseases: Official Publication Infect Dis Soc Am"},{"issue":"4","key":"801_CR4","first-page":"174","volume":"38","author":"C Gudiol","year":"2020","unstructured":"Gudiol C, Aguilar-Guisado M, Azanza JR, et al. Executive summary of the consensus document of the Spanish society of infectious diseases and clinical microbiology (SEIMC), the Spanish network for research in infectious diseases (REIPI) and the Spanish society of haematology and haemotherapy (SEHH) on the management of febrile neutropenia in patients with hematological malignancies. Enfermedades Infecciosas Y Microbiol Clin (English Ed). 2020;38(4):174\u201381.","journal-title":"Enfermedades Infecciosas Y Microbiol Clin (English Ed)"},{"issue":"4","key":"801_CR5","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.cmi.2021.09.001","volume":"28","author":"J Molina","year":"2022","unstructured":"Molina J, Montero-Mateos E, Praena-Segovia J, et al. Seven-versus 14-day course of antibiotics for the treatment of bloodstream infections by enterobacterales: a randomized, controlled trial. Clin Microbiol Infection: Official Publication Eur Soc Clin Microbiol Infect Dis. 2022;28(4):550\u20137.","journal-title":"Clin Microbiol Infection: Official Publication Eur Soc Clin Microbiol Infect Dis"},{"key":"801_CR6","first-page":"1091","volume-title":"Seven versus 14 days of antibiotic therapy for uncomplicated Gram-negative bacteremia: A noninferiority randomized controlled Trial","author":"D Yahav","year":"2019","unstructured":"Yahav D, Franceschini E, Koppel F, et al. Seven versus 14 days of antibiotic therapy for uncomplicated Gram-negative bacteremia: A noninferiority randomized controlled Trial. Volume 69. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America; 2019. pp. 1091\u20138. 7."},{"issue":"21","key":"801_CR7","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1001\/jama.2020.6348","volume":"323","author":"E von Dach","year":"2020","unstructured":"von Dach E, Albrich WC, Brunel AS, et al. Effect of C-Reactive Protein-Guided antibiotic treatment duration, 7-Day treatment, or 14-Day treatment on 30-Day clinical failure rate in patients with uncomplicated Gram-Negative bacteremia: A randomized clinical Trial. JAMA. 2020;323(21):2160\u20139.","journal-title":"JAMA"},{"issue":"1","key":"801_CR8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jinf.2022.08.037","volume":"86","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Lin Q, Zhang T, et al. Pseudomonas aeruginosa bloodstream infection in patients with hematological diseases: clinical outcomes and prediction model of multidrug-resistant infections. J Infect. 2023;86(1):66\u2013117.","journal-title":"J Infect"},{"issue":"Suppl 4","key":"801_CR9","doi-asserted-by":"publisher","first-page":"S386","DOI":"10.1093\/cid\/ciaa1522","volume":"71","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Lin Q, Liu L, et al. Risk factors and outcomes of Antibiotic-resistant Pseudomonas aeruginosa bloodstream infection in adult patients with acute Leukemia. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2020;71(Suppl 4):S386\u201393.","journal-title":"Clin Infect Diseases: Official Publication Infect Dis Soc Am"},{"key":"801_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fcimb.2015.00011","volume":"5","author":"R Moghnieh","year":"2015","unstructured":"Moghnieh R, Estaitieh N, Mugharbil A, et al. Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis. Front Cell Infect Microbiol. 2015;5:11.","journal-title":"Front Cell Infect Microbiol"},{"issue":"5","key":"801_CR11","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ijantimicag.2019.02.001","volume":"53","author":"CE Luyt","year":"2019","unstructured":"Luyt CE, Faure M, Bonnet I, et al. Use of non-carbapenem antibiotics to treat severe extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae infections in intensive care unit patients. Int J Antimicrob Agents. 2019;53(5):547\u201352.","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"801_CR12","doi-asserted-by":"publisher","first-page":"4159","DOI":"10.1128\/AAC.00365-16","volume":"60","author":"B Guti\u00e9rrez-Guti\u00e9rrez","year":"2016","unstructured":"Guti\u00e9rrez-Guti\u00e9rrez B, P\u00e9rez-Galera S, Salamanca E, et al. A multinational, preregistered cohort study of \u03b2-Lactam\/\u03b2-Lactamase inhibitor combinations for treatment of bloodstream infections due to Extended-Spectrum-\u03b2-Lactamase-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2016;60(7):4159\u201369.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"801_CR13","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1001\/jama.2018.12163","volume":"320","author":"PNA Harris","year":"2018","unstructured":"Harris PNA, Tambyah PA, Lye DC, et al. Effect of Piperacillin-Tazobactam vs meropenem on 30-Day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: A randomized clinical Trial. JAMA. 2018;320(10):984\u201394.","journal-title":"JAMA"},{"issue":"5","key":"801_CR14","doi-asserted-by":"publisher","first-page":"503","DOI":"10.6004\/jnccn.2023.0025","volume":"21","author":"DA Pollyea","year":"2023","unstructured":"Pollyea DA, Altman JK, Assi R, et al. Acute myeloid leukemia, version 3.2023, NCCN clinical practice guidelines in Oncology. J Natl Compr Cancer Network: JNCCN. 2023;21(5):503\u201313.","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"issue":"11","key":"801_CR15","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.6004\/jnccn.2021.0054","volume":"19","author":"AD Zelenetz","year":"2021","unstructured":"Zelenetz AD, Gordon LI, Chang JE, et al. NCCN Guidelines\u00ae insights: B-Cell lymphomas, version 5.2021. J Natl Compr Cancer Network: JNCCN. 2021;19(11):1218\u201330.","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"key":"801_CR16","doi-asserted-by":"crossref","unstructured":"Chotiprasitsakul D, Han JH, Cosgrove SE, et al. Comparing the outcomes of adults with Enterobacteriaceae bacteremia receiving Short-Course versus Prolonged-Course antibiotic therapy in a multicenter, propensity Score\u2013Matched Cohort. Volume 66. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America,; 2018. pp. 172\u20137. 2.","DOI":"10.1093\/cid\/cix767"},{"key":"801_CR17","doi-asserted-by":"crossref","unstructured":"Giannella M, Pascale R, Toschi A et al. Treatment duration for Escherichia coli bloodstream infection and outcomes: retrospective single-centre study. clinical microbiology and infection: the official publication of the European society of clinical microbiology and infectious diseases, 2018, 24(10): 1077\u201383.","DOI":"10.1016\/j.cmi.2018.01.013"},{"issue":"5","key":"801_CR18","doi-asserted-by":"publisher","first-page":"e14085","DOI":"10.1111\/tid.14085","volume":"25","author":"N Ranganath","year":"2023","unstructured":"Ranganath N, Yetmar ZA, McCandless AR, et al. Evaluating antimicrobial duration for Gram-negative bacteremia in patients with neutropenia due to hematologic malignancy or hematopoietic stem cell transplantation. Transpl Infect Disease: Official J Transplantation Soc. 2023;25(5):e14085.","journal-title":"Transpl Infect Disease: Official J Transplantation Soc"},{"issue":"1","key":"801_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jinf.2017.10.009","volume":"76","author":"M Mikulska","year":"2018","unstructured":"Mikulska M, Averbuch D, Tissot F, et al. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. J Infect. 2018;76(1):20\u201337.","journal-title":"J Infect"},{"issue":"9","key":"801_CR20","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1182\/bloodadvances.2022008226","volume":"7","author":"D Clerici","year":"2023","unstructured":"Clerici D, Galli L, Greco R, et al. Levofloxacin prophylaxis vs no prophylaxis in patients with neutropenia within an endemic country for carbapenem-resistant GNB. Blood Adv. 2023;7(9):1621\u201334.","journal-title":"Blood Adv"},{"issue":"1","key":"801_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jinf.2021.10.017","volume":"84","author":"A Metais","year":"2022","unstructured":"Metais A, Torregrosa Diaz JM, Gallego Hernanz MP, et al. Efficacy of antibiotic short course for bloodstream infections in acute myeloid leukemia patients with febrile neutropenia: A retrospective comparative study. J Infect. 2022;84(1):1\u20137.","journal-title":"J Infect"},{"key":"801_CR22","first-page":"ciad428","volume-title":"Infectious diseases society of America 2023 guidance on the treatment of antimicrobial resistant Gram-Negative Infections","author":"PD Tamma","year":"2023","unstructured":"Tamma PD, Aitken SL, Bonomo RA, et al. Infectious diseases society of America 2023 guidance on the treatment of antimicrobial resistant Gram-Negative Infections. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America; 2023. p. ciad428."},{"issue":"11","key":"801_CR23","doi-asserted-by":"publisher","first-page":"e3842","DOI":"10.1093\/cid\/ciaa1479","volume":"73","author":"A Henderson","year":"2021","unstructured":"Henderson A, Paterson DL, Chatfield MD, et al. Association between minimum inhibitory concentration, Beta-lactamase genes and mortality for patients treated with Piperacillin\/Tazobactam or meropenem from the MERINO Study. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2021;73(11):e3842\u201350.","journal-title":"Clin Infect Diseases: Official Publication Infect Dis Soc Am"},{"issue":"8","key":"801_CR24","doi-asserted-by":"publisher","first-page":"e00164","DOI":"10.1128\/AAC.00164-17","volume":"61","author":"C Gudiol","year":"2017","unstructured":"Gudiol C, Royo-Cebrecos C, Abdala E, et al. Efficacy of \u03b2-Lactam\/\u03b2-Lactamase inhibitor combinations for the treatment of bloodstream infection due to Extended-Spectrum-\u03b2-Lactamase-Producing Enterobacteriaceae in hematological patients with Neutropenia. Antimicrob Agents Chemother. 2017;61(8):e00164\u201317.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"801_CR25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12941-021-00471-6","volume":"20","author":"H Luo","year":"2021","unstructured":"Luo H, Xiao Y, Hang Y, et al. Comparison of therapy with \u03b2-lactam\/\u03b2-lactamase inhibitor combinations or carbapenems for bacteraemia of nonurinary source caused by ESBL-producing Escherichia coli or Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob. 2021;20(1):63.","journal-title":"Ann Clin Microbiol Antimicrob"}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-025-00801-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12941-025-00801-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-025-00801-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T13:59:30Z","timestamp":1748527170000},"score":1,"resource":{"primary":{"URL":"https:\/\/ann-clinmicrob.biomedcentral.com\/articles\/10.1186\/s12941-025-00801-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["801"],"URL":"https:\/\/doi.org\/10.1186\/s12941-025-00801-y","relation":{},"ISSN":["1476-0711"],"issn-type":[{"value":"1476-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"assertion":[{"value":"16 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by the ethical committee of the Institute of Hematology and Blood Diseases Hospital. Due to the anonymous retrospective nature of the analysis, the ethics committee waived the written informed consent. It was conducted in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}